Antibody and Immunomodulatory Agents in the Treatment of Indolent Non-Hodgkin's Lymphoma

Seminars in Hematology

Volumn 45, Issue 2, 2008, Pages 85-89

  LaCasce, Ann S ^a   Freedman, Arnold S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIIDIOTYPIC ANTIBODY; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; RITUXIMAB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; HUMAN; LOW DRUG DOSE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, NON-HODGKIN; OLIGONUCLEOTIDES;

EID: 41149173823     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.02.004     Document Type: Article

References (41)

1. Nadler L.M., Stashenko P., Hardy R., Kaplan W.D., Button L.N., Kufe D.W., et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40 (1980) 3147-3154
2. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
3. Ghielmini M., Schmitz S.F., Cogliatti S.B., Pichert G., Hummerjohann J., Waltzer U., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103 (2004) 4416-4423
4. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
5. Multani P.S., and Grossbard M.L. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 16 (1998) 3691-3710
6. Maloney D.G., Smith B., and Rose A. Rituximab: Mechanism of action and resistance. Semin Oncol 29 suppl 2 (2002) 2-9
7. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22 (2003) 7359-7368
8. Cragg M.S., Morgan S.M., Chan H.T., Morgan B.P., Filatov A.V., Johnson P.W., et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101 (2003) 1045-1052
9. van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., Hack C.E., and van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115 (2001) 807-811
10. Shan D., Ledbetter J.A., and Press O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48 (2000) 673-683
11. Ghetie M.A., Bright H., and Vitetta E.S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97 (2001) 1392-1398
12. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., et al. Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64 (2004) 4664-4669
13. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 (2000) 3900-3908
14. Voso M.T., Pantel G., Rutella S., Weis M., D'Alo F., Urbano R., et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 87 (2002) 918-925
15. Ghielmini M., Rufibach K., Salles G., Leoncini-Franscini L., Leger-Falandry C., Cogliatti S., et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16 (2005) 1675-1682
16. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
17. Fisher R.I., Dana B.W., LeBlanc M., Kjeldsberg C., Forman J.D., Unger J.M., et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 18 (2000) 2010-2016
18. Cheson B.D. The curious case of the baffling biological. J Clin Oncol 18 (2000) 2007-2009
19. Davis T.A., Maloney D.G., Grillo-Lopez A.J., White C.A., Williams M.E., Weiner G.J., et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 6 (2000) 2644-2652
20. Sacchi S., Federico M., Vitolo U., Boccomini C., Vallisa D., Baldini L., et al. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 86 (2001) 951-958
21. Malik U.R., Makower D.F., and Wadler S. Interferon-mediated fatigue. Cancer 92 suppl (2001) 1664-1668
22. Friedberg J.W., Neuberg D., Gribben J.G., Fisher D.C., Canning C., Koval M., et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 117 (2002) 828-834
23. Gluck W.L., Hurst D., Yuen A., Levine A.M., Dayton M.A., Gockerman J.P., et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10 (2004) 2253-2264
24. Khan K.D., Emmanouilides C., Benson Jr. D.M., Hurst D., Garcia P., Michelson G., et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 12 (2006) 7046-7053
25. Rohatiner A.Z., Gregory W.M., Peterson B., Borden E., Solal-Celigny P., Hagenbeek A., et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23 (2005) 2215-2223
26. Gollob J.A., Veenstra K.G., Parker R.A., Mier J.W., McDermott D.F., Clancy D., et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21 (2003) 2564-2573
27. Ansell S.M., Witzig T.E., Kurtin P.J., Sloan J.A., Jelinek D.F., Howell K.G., et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99 (2002) 67-74
28. Ansell S.M., Geyer S.M., Maurer M.J., Kurtin P.J., Micallef I.N., Stella P., et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res 12 (2006) 6056-6063
29. Liu N.S.G.E., Poindexter N.J., Reuben J.M., Rodriguez M.A., Hagemeister F.B., et al. Rituximab, alone and in combination, for treatment of patients with indolent B cell lymphoma. Am J Oncol Rev 8 suppl 10 (2005) 27-33
30. van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., and van Oers M.H. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy. Leukemia 17 (2003) 1658-1664
31. Kimby E. Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor. Semin Oncol 29 suppl 6 (2002) 7-10
32. Hsu F.J., Caspar C.B., Czerwinski D., Kwak L.W., Liles T.M., Syrengelas A., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-Long-term results of a clinical trial. Blood 89 (1997) 3129-3135
33. Qin Z., Richter G., Schuler T., Ibe S., Cao X., and Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4 (1998) 627-630
34. Koc O.N., Redfern C., Wiernik P.H., Rosenfelt F., Winter J.N., Guthrie T.H., et al. Active immunotherapy with FavId (Id/KLH) following rituximab induction: Long-term follow-up of response rate improvement (RRI) and disease progression in follicular lymphoma patients (pts). Blood 108 (2006) 691 (abstr)
35. Koc O.N., Redfern C., Wiernik P.H., Rosenfelt F., Winter J.N., Guthrie T.H., et al. Extended follow-up and analysis with central radiological review of patients receiving FavId (Id/KLH) vaccine following rituximab. Blood 106 (2005) 772 (abstr)
36. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4 (2004) 249-258
37. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., and Hammerling G.J. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 167 (2001) 5247-5253
38. Jahrsdorfer B., Hartmann G., Racila E., Jackson W., Muhlenhoff L., Meinhardt G., et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 69 (2001) 81-88
39. Link B.K., Ballas Z.K., Weisdorf D., Wooldridge J.E., Bossler A.D., Shannon M., et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29 (2006) 558-568
40. Friedberg J.W., Kelly J., Kutok J., Salloum R., Fisher D.C., Ronan E., et al. Combination Immunotherapy with a CpG oligonucleotide and rituximab (R) augments the immunological response and favorably alters the malignant microenvironment of follicular lymphoma (FL). Blood 108 (2006) 2713 (abstr)
41. Leonard J.P., Link B.K., Emmanouilides C., Gregory S., Weisdorf D., Andrey J., et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 13 (2007) 6168-6174